Alaa Elkordy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alaa Elkordy has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Eman H. Basha
Tanta University
4 shared publications - Heba Faheem
Department of Physiology, Faculty of Medicine Tanta University Tanta Egypt
4 shared publications - Fatma H. Rizk
Tanta University
3 shared publications - Radwa Ismail
Tanta University
3 shared publications - Abdallah A. Homouda
Department of Urology, Faculty of Medicine Tanta University Tanta Egypt
2 shared publications - Ahmed Mohamed Elhfnawy
Department of Neurology, University of Alexandria, Alexandria, Egypt
2 shared publications
Latest Publications
- 27 August 2025
- Published by Wiley in Comprehensive Physiology
- Vol. 15 (5) , e70039
Nesfatin‐1 Exerts a Neuroprotective Effect in Thioacetamide‐Induced Acute Hepatic Encephalopathy by Activating the PI3K /Akt/Nrf2/ HO ‐1 Pathway
Introduction: Hepatic encephalopathy (HE) is a neuropsychiatric disorder associated with liver failure. Nesfatin‐1 is a neuropeptide characterized by its antioxidant and anti‐inflammatory properties. Aim: This study aimed to evaluate the neuroprotective and hepatoprotective effects of nesfatin‐1 in a thioacetamide (TAA)‐induced rat model of acute HE. Additionally, the study aimed to examine the underlying mechanisms, particularly the role of the PI3K/Akt/Nrf2/HO‐1 signaling pathway. Materials and Methods: Male Sprague Dawley rats were divided into five groups: (1) untreated control, (2) nesfatin‐1‐treated control, (3) thioacetamide‐induced hepatic encephalopathy (HE), (4) HE + nesfatin‐1, and (5) HE + nesfatin‐1 + zinc protoporphyrin IX (ZnPP IX; HO‐1 inhibitor). Assessments included behavioral analysis, serum liver function biomarkers, oxidative stress and inflammatory markers, brain water content, mRNA expression of HO‐1 (Heme Oxygenase 1) and GFAP (Glial Fibrillary Acidic Protein), PI3K/Akt/Nrf2 protein levels, as well as histological and immunohistochemical evaluations. Results: Nesfatin‐1 significantly improved psychomotor activity, reduced serum ALT, AST, total bilirubin, and ammonia levels, and increased albumin. It also lowered brain MDA, TNF‐α, IL‐6, and CRP levels, reduced brain water content, and upregulated the expression of HO‐1 and GFAP. Furthermore, nesfatin‐1 activated the PI3K/Akt/Nrf2 pathway and inhibited the expression of caspase‐3 and NF‐κB in liver and brain tissues. These protective effects were negated by HO‐1 inhibition using ZnppIX. Histological analysis demonstrated the structural integrity of liver and brain tissues in rats treated with nesfatin‐1. Conclusion: Nesfatin‐1 exerts potent hepatoprotective and neuroprotective effects in TAA‐induced hepatic encephalopathy via antioxidative, anti‐inflammatory, and antiapoptotic mechanisms involving the PI3K/Akt/Nrf2/HO‐1 pathway.
- 27 August 2025
- Published by Wiley in Comprehensive Physiology
- Vol. 15 (5) , e70039
Nesfatin‐1 Exerts a Neuroprotective Effect in Thioacetamide‐Induced Acute Hepatic Encephalopathy by Activating the PI3K /Akt/Nrf2/ HO ‐1 Pathway
Introduction: Hepatic encephalopathy (HE) is a neuropsychiatric disorder associated with liver failure. Nesfatin‐1 is a neuropeptide characterized by its antioxidant and anti‐inflammatory properties. Aim: This study aimed to evaluate the neuroprotective and hepatoprotective effects of nesfatin‐1 in a thioacetamide (TAA)‐induced rat model of acute HE. Additionally, the study aimed to examine the underlying mechanisms, particularly the role of the PI3K/Akt/Nrf2/HO‐1 signaling pathway. Materials and Methods: Male Sprague Dawley rats were divided into five groups: (1) untreated control, (2) nesfatin‐1‐treated control, (3) thioacetamide‐induced hepatic encephalopathy (HE), (4) HE + nesfatin‐1, and (5) HE + nesfatin‐1 + zinc protoporphyrin IX (ZnPP IX; HO‐1 inhibitor). Assessments included behavioral analysis, serum liver function biomarkers, oxidative stress and inflammatory markers, brain water content, mRNA expression of HO‐1 (Heme Oxygenase 1) and GFAP (Glial Fibrillary Acidic Protein), PI3K/Akt/Nrf2 protein levels, as well as histological and immunohistochemical evaluations. Results: Nesfatin‐1 significantly improved psychomotor activity, reduced serum ALT, AST, total bilirubin, and ammonia levels, and increased albumin. It also lowered brain MDA, TNF‐α, IL‐6, and CRP levels, reduced brain water content, and upregulated the expression of HO‐1 and GFAP. Furthermore, nesfatin‐1 activated the PI3K/Akt/Nrf2 pathway and inhibited the expression of caspase‐3 and NF‐κB in liver and brain tissues. These protective effects were negated by HO‐1 inhibition using ZnppIX. Histological analysis demonstrated the structural integrity of liver and brain tissues in rats treated with nesfatin‐1. Conclusion: Nesfatin‐1 exerts potent hepatoprotective and neuroprotective effects in TAA‐induced hepatic encephalopathy via antioxidative, anti‐inflammatory, and antiapoptotic mechanisms involving the PI3K/Akt/Nrf2/HO‐1 pathway.
- Open Access
- 1 July 2025
- Published by Elsevier in World Neurosurgery
- p. 124226
Feasibility and Efficacy of Venous Sinus Stenting for Idiopathic Intracranial Hypertension in a non-Western Country
- 1 July 2025
- Published by Elsevier in World Neurosurgery
- p. 124226
Open AccessFeasibility and Efficacy of Venous Sinus Stenting for Idiopathic Intracranial Hypertension in a non-Western Country
- 10 June 2025
- Published by Wiley in Australasian Journal of Ultrasound in Medicine
- Vol. 28 (3) , e70010
Frequency and Predictors of Ultrasound‐Detected Extracranial Vertebral Artery Stenosis in a Sample of Non‐Western Population
Objective: Extracranial vertebral artery (VA) stenosis represents an important aetiology of ischaemic vascular events in the posterior circulation. Nevertheless, it remains insufficiently investigated. Ethnic differences might be related to VA stenosis. In this regard, Egyptian studies are scarce. We aimed to investigate the frequency and predictors of extracranial VA stenosis in a sample of Egyptian patients.Methods: We enrolled consecutive patients who were referred to our neurovascular ultrasonography laboratory for routine clinical indications. Extracranial VA stenosis was diagnosed and graded using ultrasound.Results: We included 528 patients in our study. Significant extracranial VA stenosis ≥ 50% was found among 10.4% (n = 10/96) of patients with ischaemic vascular events in the posterior circulation and 4.2% (n = 18/432) of patients without (p = 0.01). One patient received stenting for VA origin stenosis. Carotid atherosclerosis was present in 82.1% (n = 23/28) of patients with significant extracranial VA stenosis in comparison with 47.6% (n = 238/500) of those without (p < 0.001). In an age‐ and sex‐adjusted multivariate binary logistic regression, the following factors predicted significant extracranial VA stenosis: age > 60 years (OR 2.68, 95% CI 1.08–6.66, p = 0.03), significant common/internal carotid artery (CCA/ICA) stenosis ≥ 50% (OR 4.81, 95% CI 1.89–12.29, p = 0.001) and ischaemic vascular events in the posterior circulation (OR 2.78, 95% CI 1.17–6.65, p = 0.02).Conclusions: The frequency of extracranial VA stenosis seems to be lower among Egyptians in comparison with Western cohorts. Among patients with carotid atherosclerosis or significant CCA/ICA stenosis and/or ischaemic vascular events in the posterior circulation, meticulous ultrasound examination of the VA is warranted to detect possibly underlying extracranial VA stenosis.
- 10 June 2025
- Published by Wiley in Australasian Journal of Ultrasound in Medicine
- Vol. 28 (3) , e70010
Frequency and Predictors of Ultrasound‐Detected Extracranial Vertebral Artery Stenosis in a Sample of Non‐Western Population
Objective: Extracranial vertebral artery (VA) stenosis represents an important aetiology of ischaemic vascular events in the posterior circulation. Nevertheless, it remains insufficiently investigated. Ethnic differences might be related to VA stenosis. In this regard, Egyptian studies are scarce. We aimed to investigate the frequency and predictors of extracranial VA stenosis in a sample of Egyptian patients.Methods: We enrolled consecutive patients who were referred to our neurovascular ultrasonography laboratory for routine clinical indications. Extracranial VA stenosis was diagnosed and graded using ultrasound.Results: We included 528 patients in our study. Significant extracranial VA stenosis ≥ 50% was found among 10.4% (n = 10/96) of patients with ischaemic vascular events in the posterior circulation and 4.2% (n = 18/432) of patients without (p = 0.01). One patient received stenting for VA origin stenosis. Carotid atherosclerosis was present in 82.1% (n = 23/28) of patients with significant extracranial VA stenosis in comparison with 47.6% (n = 238/500) of those without (p < 0.001). In an age‐ and sex‐adjusted multivariate binary logistic regression, the following factors predicted significant extracranial VA stenosis: age > 60 years (OR 2.68, 95% CI 1.08–6.66, p = 0.03), significant common/internal carotid artery (CCA/ICA) stenosis ≥ 50% (OR 4.81, 95% CI 1.89–12.29, p = 0.001) and ischaemic vascular events in the posterior circulation (OR 2.78, 95% CI 1.17–6.65, p = 0.02).Conclusions: The frequency of extracranial VA stenosis seems to be lower among Egyptians in comparison with Western cohorts. Among patients with carotid atherosclerosis or significant CCA/ICA stenosis and/or ischaemic vascular events in the posterior circulation, meticulous ultrasound examination of the VA is warranted to detect possibly underlying extracranial VA stenosis.
- 2 March 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (3) , e70196
The Protective Effects of Saxagliptin and Cilostazol in an Experimental Model of Cyclophosphamide‐Induced Nephrotoxicity in Rats: Targeting iNOS/NF‐kB and Nrf‐2/HO‐1 Pathways
Cyclophosphamide (CYP) is an extensively used immunosuppressive drug and chemotherapeutic agent for various malignancies. Nevertheless, its use is limited due to adverse effects, including nephrotoxicity. Saxagliptin is a DPP4 inhibitor, while cilostazol serves as an antiplatelet agent. Their nephroprotective effects arise from antioxidant and anti‐inflammatory properties. This study investigated the potential protective effects of Saxagliptin and Cilostazol in rats with kidney damage induced by CYP. Five equal groups of 50 male Wistar rats were randomly categorised as Group I (Control group), Group II: CYP untreated nephrotoxicity–induced group, Group III: Nephrotoxicity‐induced group treated with saxagliptin, Group IV: Nephrotoxicity‐induced group treated with cilostazol, and Group V: Nephrotoxicity‐induced group treated with saxagliptin and cilostazol. Renal tissues and blood samples were collected for biochemical analysis of urea, creatinine, and acute kidney injury biomarkers, including Kim‐1 and NGAL. Additionally, oxidative stress and inflammatory biomarkers such as GSH, MDA, TNF‐α and IL‐1β were assessed, along with gene expression of Nrf‐2/HO‐1 and NF‐kB. Immunohistochemical analysis of iNOS, and histopathological study were also conducted. Saxagliptin and cilostazol ameliorated the nephrotoxicity induced by CYP, as indicated by improvements in urea, creatinine, and acute kidney injury biomarkers Kim‐1 and NGAL. Furthermore, there was a decrease in oxidative stress via the upregulation of Nrf‐2/HO‐1, increased levels of GSH, downregulation of MDA and decreased inflammation via the downregulation of TNF‐α, IL‐1β and iNOS/NF‐kB. The combination of saxagliptin and cilostazol demonstrated a significant improvement compared to using each agent individually. The combination of Saxagliptin/Cilostazol is superior to monotherapy by either of each alone in preventing CYP‐induced nephrotoxicity.
- 2 March 2025
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 39 (3) , e70196
The Protective Effects of Saxagliptin and Cilostazol in an Experimental Model of Cyclophosphamide‐Induced Nephrotoxicity in Rats: Targeting iNOS/NF‐kB and Nrf‐2/HO‐1 Pathways
Cyclophosphamide (CYP) is an extensively used immunosuppressive drug and chemotherapeutic agent for various malignancies. Nevertheless, its use is limited due to adverse effects, including nephrotoxicity. Saxagliptin is a DPP4 inhibitor, while cilostazol serves as an antiplatelet agent. Their nephroprotective effects arise from antioxidant and anti‐inflammatory properties. This study investigated the potential protective effects of Saxagliptin and Cilostazol in rats with kidney damage induced by CYP. Five equal groups of 50 male Wistar rats were randomly categorised as Group I (Control group), Group II: CYP untreated nephrotoxicity–induced group, Group III: Nephrotoxicity‐induced group treated with saxagliptin, Group IV: Nephrotoxicity‐induced group treated with cilostazol, and Group V: Nephrotoxicity‐induced group treated with saxagliptin and cilostazol. Renal tissues and blood samples were collected for biochemical analysis of urea, creatinine, and acute kidney injury biomarkers, including Kim‐1 and NGAL. Additionally, oxidative stress and inflammatory biomarkers such as GSH, MDA, TNF‐α and IL‐1β were assessed, along with gene expression of Nrf‐2/HO‐1 and NF‐kB. Immunohistochemical analysis of iNOS, and histopathological study were also conducted. Saxagliptin and cilostazol ameliorated the nephrotoxicity induced by CYP, as indicated by improvements in urea, creatinine, and acute kidney injury biomarkers Kim‐1 and NGAL. Furthermore, there was a decrease in oxidative stress via the upregulation of Nrf‐2/HO‐1, increased levels of GSH, downregulation of MDA and decreased inflammation via the downregulation of TNF‐α, IL‐1β and iNOS/NF‐kB. The combination of saxagliptin and cilostazol demonstrated a significant improvement compared to using each agent individually. The combination of Saxagliptin/Cilostazol is superior to monotherapy by either of each alone in preventing CYP‐induced nephrotoxicity.
- 1 March 2025
- Published by American Physiological Society in Physiological Genomics
- Vol. 57 (3) , 103-114
Ameliorating immune-dependent inflammation and apoptosis by targeting TLR4/MYD88/NF-κB pathway by celastrol mitigates the diabetic reproductive dysfunction
Celastrol inhibits the production of proinflammatory cytokines in the testicular tissue by specifically targeting the TLR4/MyD88/NF- κB signaling cascade pathways. This indicates that celastrol may serve as a promising new therapeutic target for treating diabetic reproductive dysfunction.
- 1 March 2025
- Published by American Physiological Society in Physiological Genomics
- Vol. 57 (3) , 103-114
Ameliorating immune-dependent inflammation and apoptosis by targeting TLR4/MYD88/NF-κB pathway by celastrol mitigates the diabetic reproductive dysfunction
Celastrol inhibits the production of proinflammatory cytokines in the testicular tissue by specifically targeting the TLR4/MyD88/NF- κB signaling cascade pathways. This indicates that celastrol may serve as a promising new therapeutic target for treating diabetic reproductive dysfunction.
- 31 July 2024
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 28 (4) , 448-470
The potential neuroprotective effects of Spirulina platensis in a valproic acid-induced experimental model of autism in the siblings of albino rats: targeting PIk3/AKT/mTOR signalling pathway
Introduction: Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders with poor social interaction, communication issues, aberrant motor movements, and limited repetitive interests and behaviour. Spirulina platensis (SP) contains several multi-nutrients and has a wide range of neuroprotective properties.Aim: The target of the current experiment is to detect the protective effects of S. platensis on valproic-induced autism in adult female albino rats' siblings for the first time.Materials and Methods: Twelve Pregnant rats were separated into four main groups; Group I (control); Group II (S. platensis); Group III (autistic group); and Group IV (autistic SP-treated group). Fifteen offspring pups from each group were sacrificed, brain was divided for biochemical analysis as superoxide dismutase and malondialdehyde were evaluated spectrophotometrically while interleukin-6, interleukin-12, Bcl-2-associated X protein, B-cell lymphoma-2, Beclin-1, brain-derived neurotrophic factor were assessed by ELISA, other division of brain were used for gene expression of PI3k, Akt and mTOR pathway, last division of brain were stained using (H&E) and Giemsa stains. Tumour necrosis factor alpha (TNF- and Synaptophysin (SYN) markers were used for immunohistochemical staining.Results: Autistic Group (III) showed an increment in levels of MDA, IL-6, IL12 and BAX while showing a decrement in SOD, Bcl-2 and Beclin-1 as well as increased PI3k, Akt and mTOR gene expression. Autistic Group (III) also exhibited hypocellularity and disorganization of hippocampal and prefrontal cortex cells. The autistic SP-treated group (IV) showed improvement in these biochemical markers and pathological changes. Our findings suggest that Spirulina platensis will be significant in managing autism.- 31 July 2024
- Published by Taylor & Francis in Nutritional Neuroscience
- Vol. 28 (4) , 448-470
The potential neuroprotective effects of Spirulina platensis in a valproic acid-induced experimental model of autism in the siblings of albino rats: targeting PIk3/AKT/mTOR signalling pathway
Introduction: Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders with poor social interaction, communication issues, aberrant motor movements, and limited repetitive interests and behaviour. Spirulina platensis (SP) contains several multi-nutrients and has a wide range of neuroprotective properties.Aim: The target of the current experiment is to detect the protective effects of S. platensis on valproic-induced autism in adult female albino rats' siblings for the first time.Materials and Methods: Twelve Pregnant rats were separated into four main groups; Group I (control); Group II (S. platensis); Group III (autistic group); and Group IV (autistic SP-treated group). Fifteen offspring pups from each group were sacrificed, brain was divided for biochemical analysis as superoxide dismutase and malondialdehyde were evaluated spectrophotometrically while interleukin-6, interleukin-12, Bcl-2-associated X protein, B-cell lymphoma-2, Beclin-1, brain-derived neurotrophic factor were assessed by ELISA, other division of brain were used for gene expression of PI3k, Akt and mTOR pathway, last division of brain were stained using (H&E) and Giemsa stains. Tumour necrosis factor alpha (TNF- and Synaptophysin (SYN) markers were used for immunohistochemical staining.Results: Autistic Group (III) showed an increment in levels of MDA, IL-6, IL12 and BAX while showing a decrement in SOD, Bcl-2 and Beclin-1 as well as increased PI3k, Akt and mTOR gene expression. Autistic Group (III) also exhibited hypocellularity and disorganization of hippocampal and prefrontal cortex cells. The autistic SP-treated group (IV) showed improvement in these biochemical markers and pathological changes. Our findings suggest that Spirulina platensis will be significant in managing autism.- 1 June 2019
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 64, 206-213
Neuroprotective effects of minocycline and progesterone on white matter injury after focal cerebral ischemia
- 1 June 2019
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 64, 206-213
Neuroprotective effects of minocycline and progesterone on white matter injury after focal cerebral ischemia